GlycoMimetics completes two Phase I sickle cell disease trials
GlycoMimetics, a clinical stage pharmaceutical company, has completed two Phase I safety studies of its lead drug candidate GMI-1070 for vaso-occlusive crisis of sickle cell disease. The Phase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.